Thanks — really appreciate your response and how you’ve framed...

Thanks — really appreciate your response and how you’ve framed it.You’re right: if the OSLOBs expire, any future raise would likely involve issuing new shares, and yes, that could include free oppies depending on the structure. But I’d argue the market’s already factoring in the OSLOB dilution. If they expire and we raise fresh capital, it’s not necessarily more dilution — just a different version of what’s already priced in. In some scenarios, the total shares issued could even be less than if all 1.91B OSLOBs converted.Also, if we get some solid traction — strong G-BA numbers, FDA HDE progress, or a commercial catalyst — the raise might not need to be as large or as discounted. And if it’s a placement to a strategic or institutional investor, we might avoid oppies altogether and strengthen the register.So yeah, fair concerns — but there are a few ways this could still play out constructively.